INTRODUCTION AND OBJECTIVES: Overactive bladder (OAB) is characterized by urinary urgency, frequency, nocturia, and urinary incontinence (UI). The prevalence of OAB increases significantly with age. The first-line therapy for OAB is antimuscarinic medication, some of which have deleterious side-effects, including cognitive decline. We sought to examine the incidence and prevalence of antimuscarinic prescriptions among elderly persons ¼ age 65.
INTRODUCTION AND OBJECTIVES: Overactive bladder (OAB) is characterized by urinary urgency, frequency, nocturia, and urinary incontinence (UI). The prevalence of OAB increases significantly with age. The first-line therapy for OAB is antimuscarinic medication, some of which have deleterious side-effects, including cognitive decline. We sought to examine the incidence and prevalence of antimuscarinic prescriptions among elderly persons ¼ age 65.
METHODS: The 2006-12 National Ambulatory Medical Care Survey (NAMCS) were queried for patients with newly given or renewed prescriptions for any of 6 antimuscarinics: oxybutynin, tolterodine, fesoterodine, darifenacin, solifenacin, and trospium. Within these cohorts, frequencies of patient/physician attributes and annual trends in drug prescription were determined utilizing drug-mention weighting methodology.
RESULTS: A weighted estimate of 47.68 million individuals (unweighted n¼1,968) had their antimuscarinics renewed, and 12.77 million patients (unweighted n¼641) received a new prescription ( Table 1 ). The majority of new antimuscarinics were prescribed in elderly (¼ age 65) (55.2%), female (69.2%), white (61.7%), and Medicare insured (84.1%) individuals. Oxybutynin was a frequently prescribed (incidence 27.3%) and continued (prevalence 33.2 %) antimuscarinic among elderly patients. In 2010, there was a sharp decrease in the number of all continued antimuscarinic prescriptions, followed by annual increases in oxybutynin continuation versus continued decline in other antimuscarinic continuation ( Figure 1 ). Figure 1 : Continued Antimuscarinic Prescriptions in Patients > 65 Years of Age, NAMCS 2006-2012 CONCLUSIONS: We found alarmingly high prescription rates of oxybutynin (27.3%), pharmacologically the least suitable antimuscarinic, for which studies have consistently demonstrated higher rates of cognitive impairment in the elderly. Frequent oxybutynin prescription is likely driven by tiered Medicare formularies which require patients to trial oxybutynin, a cheaper, generic antimuscarinic, before allowing access to newer, more costly yet safer, antimuscarinics. This work is the first population-based study demonstrating both the alarming rate of oxybutynin prescription and the lack of a proper safety net for a growing and vulnerable elderly population. Our work demands an increased consideration of the possible deleterious effects of unmonitored antimuscarinic use in elderly patients.
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MP69-02 VARIATION IN CARE INTENSITY FOR OVERACTIVE BLADDER SYMPTOMS AMONG MEDICARE BENEFICIARIES
Charles Scales Jr*, Melissa Greiner, Lesley Curtis, Brad Hammill, Andrew Peterson, Cindy Amundsen, Kenneth Schmader, Durham, NC INTRODUCTION AND OBJECTIVES: Overactive bladder (OAB) affects up to 40-50% of older men and women. OAB diminishes quality of life through its impact on daily living and emotional well-being, even in the absence of urine loss. The economic costs of treating patients with OAB are projected to exceed $80 billion annually by 2020, more than half incurred by Medicare beneficiaries. Our objective was to describe variation in downstream care intensity after initial treatment of OAB symptoms among Medicare Part D beneficiaries.
METHODS: We performed a retrospective cohort study of beneficiaries using the Medicare 5% sample. Between 2007-2013, we identified beneficiaries with an outpatient encounter consistent with OAB symptoms and a Medicare Part D drug claim for pharmacotherapy. Subjects with urinary tract infection within 30 days, neurogenic bladder, and prostate cancer diagnoses were excluded. No subject had a prior OAB drug claim. We followed beneficiaries for two years after initial treatment. We used OAB-specific expenditures as a proxy for care intensity. Using a multivariable Poisson regression model with a log link, we identified associations between patient and provider characteristics and downstream OAB Medicare costs. All expenditures were inflation-adjusted to 2013 dollars.
RESULTS: During the study period, 5,337 beneficiaries had an initial drug claim and 2 years of continuous follow up. The average beneficiary was aged 78 AE 7.1 years, 80% were female, and 89% were white. In multivariable models, expenditures for Medicaid-eligible beneficiaries were 35% higher (95% CI 20-52%, p<0.001). Expenditures for individuals initially treated by urologists were 23% higher (95% CI, 11-37%, p<0.001) than those initially treated by primary care, even after controlling for urinary incontinence. Urodynamic evaluation was much more likely under the treatment of urology or gynecology specialists. Once individuals initiated treatment with a given specialty (e.g., gynecology), the vast majority continued treatment within that specialty, rather than returning to primary care.
CONCLUSIONS: Downstream OAB treatment costs vary by both patient and provider characteristics, and particularly by provider specialty, even after controlling for the presence of incontinence. Individuals are unlikely to change between specialties once treatment is initiated. To the extent that these data represent unwarranted variation in care intensity, an opportunity to improve efficiency and value of care may exist.
Source of Funding: NIH/NIA GEMSSTAR program (R03AG048130) and American Geriatric Society Dennis W. Jahnigen Career Development Award (Scales).
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